Function
While GHK-Cu acts as a tissue-remodeling and wound-healing signal, enhancing skin regeneration, angiogenesis, and repair while reducing inflammation and oxidative damage in experimental models31383, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
Mechanism
While GHK-Cu works as an endogenous tripeptide, Gly-His-Lys, that chelates Cu²⁺ and modulates gene expression, stimulating collagen, elastin, proteoglycan, and glycosaminoglycan synthesis while exerting antioxidant and anti-inflammatory effects31383, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.